MPX International Corp.

OTC: MPXOF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Toronto, ONReports USD

#689 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

——

FH —DQ —GM —SS 41

v0.1 · 5/100 weight · pillars only

↑ 3-yr revenue growth, revenue growth (YoY) · ↓ growth stability, market scale

Methodology →

Revenue TTM

$5.3M

Rev growth YoY (TTM)

+19.1%

Net income (FY)

-$21.1M

Employees

200

Market cap

$14.4k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$5.7M7.2M CAD2021

Net income-$21.1M-26.6M CAD2021

Operating income-$11.5M-14.6M CAD2021

Total assets$39.8M50.7M CAD2021

Liabilities$21.8M27.8M CAD2021

Equity$13.7M17.5M CAD2021

Revenue trend

FY2018 – FY2021 · USD

$50.2k

FY18

$1.2M

FY19

$2.4M

FY20

$5.7M

FY21

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

MPX International Corp. booked $5.7M in FY2021 revenue, growing 142% year over year — faster than most Healthcare companies we track, at a -369.4% net margin.

Peers · Healthcare

CERo Therapeutics Holdings, Inc.——Abattis Bioceuticals Corp.——Wellness Center USA, Inc.——Stemtech Corporation25D

Key facts

CEOW. Scott Boyes

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersToronto, ON

ExchangeOTC: MPXOF

Employees200

IPO date2019-03-06

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.